



(12) **United States Patent**
Kaddurah-Daouk

(10) **Patent No.:** **US 6,288,124 B1**
(45) **Date of Patent:** **Sep. 11, 2001**

(54) **METHODS OF INHIBITING UNDESIRABLE CELL GROWTH USING AN AMINO GUANIDINE COMPOUND**

(76) Inventor: **Rima Kaddurah-Daouk**, 4 Ross Rd., Belmont, MA (US) 02178

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/316,918**

(22) Filed: **May 21, 1999**

Related U.S. Application Data

(60) Provisional application No. 60/086,585, filed on May 22, 1998, and provisional application No. 60/086,504, filed on May 22, 1998.

(51) **Int. Cl.⁷** **A60K 31/155**
(52) **U.S. Cl.** **514/634**
(58) **Field of Search** 514/634

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,412,105	*	11/1968	Langis	260/340.5
5,449,688	*	9/1995	Wahl et al.	514/546
5,676,978	*	10/1997	Teicher et al.	424/649
5,994,577	*	11/1999	Larsen et al.	560/168
6,093,745	*	7/2000	Hammes et al.	514/634

FOREIGN PATENT DOCUMENTS

WO 96/16031 5/1996 (WO) .

OTHER PUBLICATIONS

Becker, S. et al., "Investigations on the function of creatine kinase in Ehrlich ascites tumor cells," *Biol. Chem. Hoppe Seyler*, 370(4):357-64 (1989),
 Feld, R.D. et al., "Presence of creatine kinase BB isoenzyme in some patients with prostatic carcinoma," *Clin. Chem.*, 23(10):1930-2 (1977).
 Gazdar, A.F. et al., "Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures," *Cancer Res.*, 41(7):2773-7 (1981).
 Homburger, H.A. et al., "Radioimmunoassay of creatine kinase B-isoenzymes in serum of patients with azotemia, obstructive uropathy, or carcinoma of the prostate or bladder," *Clin. Chem.*, 26(13):1821-4 (1980).

Ishiguro, Y. et al., "The diagnostic and prognostic value of pretreatment serum creatine kinase BB levels in patients with neuroblastoma," *Cancer*, 65(9):2014-9 (1990).

Kaddurah-Daouk, R. et al., "Induction of a cellular enzyme for energy metabolism by transforming domains of adenovirus E1a," *Mol. Cell. Biol.*, 10(4):1476-83 (1990).

Lillie, J.W. et al., "Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors," *Cancer Res.*, 3(13):3172-8 (1993).

Ohira, Y. et al., "Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed beta-guanidinopropionic acid," *Biochim. Biophys. Acta*, 1097(2):117-22 (1991).

Wallimann, T. et al., "Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phospho-creatine circuit' for cellular energy homeostasis," *Biochem. J.*, 281 (Pt 1):21-40 (1992).

* cited by examiner

Primary Examiner—Kevin E. Weddington
(74) *Attorney, Agent, or Firm*—Lahive & Cockfield, LLP; Elizabeth A. Hanley, Esq.

(57) **ABSTRACT**

The present invention provides for the use of aminoguanidines for prophylactic and/or therapeutic treatments of undesirable cell growth, e.g. tumors. The present invention provides methods of using aminoguanidines, optionally in combination with a hyperplastic inhibitory agent, to inhibit the growth of undesirable cells in a subject. The present invention is based, at least in part, on the discovery that aminoguanidines inhibit cell growth. The present invention further pertains to compositions for inhibiting undesirable cell growth in a subject. The compositions of the present invention include an effective amount of the aminoguanidine in a pharmaceutically acceptable carrier. Other aspects of the invention include a packaged aminoguanidine. The packaged compound includes instructions for using the aminoguanidine compound for inhibiting undesirable cell growth in a patient or instructions for using the compound in selected quantities, in a pharmaceutically acceptable carrier.

20 Claims, No Drawings